Immunotherapy-based targeting of MSLN⁺ activated portal fibroblasts is a strategy for treatment of cholestatic liver fibrosis

We investigated the role of mesothelin (Msln) and thymocyte differentiation antigen 1 (Thy1) in the activation of fibroblasts across multiple organs and demonstrated that Msln−/− mice are protected from cholestatic fibrosis caused by Mdr2 (multidrug resistance gene 2) deficiency, bleomycin-induced l...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Proceedings of the National Academy of Sciences - PNAS 2021-07, Vol.118 (29), p.1-12
Hauptverfasser:	Nishio, Takahiro, Koyama, Yukinori, Liu, Xiao, Rosenthal, Sara B., Yamamoto, Gen, Fuji, Hiroaki, Baglieri, Jacopo, Li, Na, Brenner, Laura N., Iwaisako, Keiko, Taura, Kojiro, Hagood, James S., LaRusso, Nicholas F., Bera, Tapan K., Pastan, Ira, Brenner, David A., Kisseleva, Tatiana
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Antigens Bile ducts Biological Sciences Bleomycin Cholestasis - drug therapy Cholestasis - genetics Cholestasis - immunology Collagen Collagen - immunology Fibroblasts Fibroblasts - drug effects Fibroblasts - immunology Fibrosis Humans Immunotherapy Immunotoxins Immunotoxins - administration & dosage Injury prevention Kidneys Liver Cirrhosis - drug therapy Liver Cirrhosis - genetics Liver Cirrhosis - immunology Mesothelin - genetics Mesothelin - immunology Mice Multidrug resistance Organs Thy-1 Antigens - genetics Thy-1 Antigens - immunology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!